cagrisema semaglutide cagrilintide combination trial 5mg + 5mg Cagrilintide–semaglutide (CagriSema) versus semaglutide or

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as key therapies for the treatment of obesity and type 2 diabetes, with several agents demonstrating cardiovascular benefits 7,8,9,10,11,12

If alternating, each cycle should last a minimum of 3 months, with 6 months being preferable

On the other hand, side effects related to stopping, such as increased hunger, food cravings and the return of food noise, may begin before the medication has fully cleared and can persist unless other weight-management strategies are in place

By making you feel fuller for extended periods of time, semaglutide naturally lowers your caloric intake

In August 2025, generic liraglutide was approved for weight loss